Literature DB >> 9295108

PET studies of functional compensation in a primate model of Parkinson's disease.

J L Eberling1, K S Bankiewicz, S Jordan, H F VanBrocklin, W J Jagust.   

Abstract

MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is a neurotoxin that produces degeneration of nigrostriatal dopaminergic neurons and a chronic parkinsonian condition in primates. Positron emission tomography (PET) studies of rhesus macaques at various time points following unilateral MPTP administration demonstrated a different time course of degeneration in the dopaminergic terminals in the putamen and in the cell bodies in the substantia nigra, consistent with other evidence of retrograde degeneration. In addition, the substantia nigra showed a transient upregulation in dopaminergic function in the lesioned hemisphere indicating functional compensation. This plasticity has important implications for the therapeutic effects of growth factors and other potential treatments for neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295108     DOI: 10.1097/00001756-199708180-00017

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  14 in total

1.  Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.

Authors:  R Pattarini; R J Smeyne; J I Morgan
Journal:  Neuroscience       Date:  2007-01-29       Impact factor: 3.590

2.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

3.  Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.

Authors:  M E Emborg; J Moirano; J Raschke; V Bondarenko; R Zufferey; S Peng; A D Ebert; V Joers; B Roitberg; J E Holden; J Koprich; J Lipton; J H Kordower; P Aebischer
Journal:  Neurobiol Dis       Date:  2009-08-04       Impact factor: 5.996

4.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

5.  Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.

Authors:  Adrian P Kells; Jamie Eberling; Xiaomin Su; Philip Pivirotto; John Bringas; Piotr Hadaczek; Wade C Narrow; William J Bowers; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  J Neurosci       Date:  2010-07-14       Impact factor: 6.167

6.  Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques.

Authors:  Christopher A Brown; Morvarid K Karimi; LinLin Tian; Hugh Flores; Yi Su; Samer D Tabbal; Susan K Loftin; Stephen M Moerlein; Joel S Perlmutter
Journal:  Ann Neurol       Date:  2013-09-16       Impact factor: 10.422

7.  Compensatory dopaminergic-cholinergic interactions in conflict processing: Evidence from patients with Parkinson's disease.

Authors:  Kamin Kim; Nicolaas I Bohnen; Martijn L T M Müller; Cindy Lustig
Journal:  Neuroimage       Date:  2018-01-11       Impact factor: 6.556

8.  Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates.

Authors:  Christine Swanson; Marina Emborg
Journal:  Neurol Res       Date:  2013-12-27       Impact factor: 2.448

9.  Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.

Authors:  Jamie L Eberling; Adrian P Kells; Philip Pivirotto; Janine Beyer; John Bringas; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

10.  The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.

Authors:  Christine R Swanson; Valerie Joers; Viktoriya Bondarenko; Kevin Brunner; Heather A Simmons; Toni E Ziegler; Joseph W Kemnitz; Jeffrey A Johnson; Marina E Emborg
Journal:  J Neuroinflammation       Date:  2011-08-05       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.